Preventing impulse control disorders in Parkinson's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if a prediction model can help prevent drug-induced impulse control disorders (like compulsive gambling or shopping) in people with Parkinson's disease who are taking dopamine agonists. It aims to lower the risk of these side effects by adjusting treatment based on the model's predictions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with Parkinson's disease for less than 6 years
- You are currently taking a dopamine agonist (a type of Parkinson's medication) for at least 2 months and plan to continue it for the next 3 years
- You do not have moderate or severe impulse control disorders (like compulsive gambling, shopping, eating, or hypersexuality) that are caused by medication
- You do not have other forms of parkinsonism (like multiple system atrophy or drug-induced parkinsonism)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of non-invasive brain stimulation called TMS can help reduce impulse control problems (like gambling or compulsive eating) that are caused by Parkinson's medications. It's for people with Parkinson's who are living with these side effects.
This trial tests if pimavanserin can reduce impulse control disorders like gambling, shopping, hypersexuality, or overeating in people with Parkinson's disease. It aims to help those whose symptoms are moderate but not too severe.
This trial tests whether deep brain stimulation (DBS) of the subthalamic nucleus can help control impulse control problems (like gambling, overeating, or shopping) in people with Parkinson's disease. It is for patients whose medication-related impulse symptoms are moderate to severe and who are good candidates for DBS surgery.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Hear when a new Impulse Control Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.